Martin Reincke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Martin Reincke has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
- Felix Beuschlein
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland
18 shared publications - Martin Bidlingmaier
Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany
7 shared publications - Bruno Allolio
Endocrinology and Diabetes Unit, Department of Internal Medicine I, University Hospital of Wuerzburg, Germany
6 shared publications - Felix Beuschlein
Abt. Innere Medizin II, Klinikum der Albert-Ludwigs-Universität Freiburg, Germany
6 shared publications - Marcus Quinkler
Endocrinology in Charlottenburg, Berlin, Germany (M.Q.).
6 shared publications Anna Riester
5 shared publications
Latest Publications
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Characteristics of aldosterone-producing adenomas: a tissue microarray study
Background: Sporadic aldosterone-producing adenomas (APA) are relevant cause of endocrine related hypertension in Primary Aldosteronism (PA). Next generation sequencing techniques have identified somatic mutations in APA harbored in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1 and PRKACA genes. Yet, a number of APA harbor no mutations in candidate genes (designated as wild type, WT) and little is known about genotype/phenotype correlation. Objectives: We investigated the tissue-based molecular and histopathological characteristics of 132 APAs after laparoscopic unilateral adrenalectomy in PA-patients and studied genotype/morphometry and histopathology correlation. Methods: Tumor-DNA was screened for somatic mutations in candidate genes by targeted (n=84) or whole-exome (n=48) sequencing. Accurate characterization of 179 morphometric parameters and of immunohistochemistry (IHC) results for steroidogenic enzymes CYP11B1, CYP11B2, CYP17, HSD3B1 and HSD3B2 was performed on tumor tissue microarrays from all samples by digital image analysis. Results: Prevalence of WT APA in our cohort was 34% and affected men more frequently. In 8/48 APA, non-recurrent somatic mutations (NR) were identified. H&E analysis demonstrated that 6 morphometric parameters correlated negatively with WT status whereas those same parameters correlated positively with the presence of KCNJ5 or NR (PWT and KCNJ5 mutated APA was found in 10 cytoplasmic parameters, including mainly color-based features (PKCNJ5 mutation status was negatively correlated with CYP11B1 and HSD3B1 expression (PWT, CACNA1D and NR APA significantly correlated positively with CYP11B1. ATP1A1 mutated APA correlated positively with CYP11B2 (PNR APA point towards a KCNJ5-like morphometric pattern associated with a WT-like steroidogenic enzymes expression pattern. WT APA presented an opposed morphometric pattern in comparison to mutated APA, indicating that in absence of detectable somatic mutations APA cells are driven towards a different cellular fate.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Characteristics of aldosterone-producing adenomas: a tissue microarray study
Background: Sporadic aldosterone-producing adenomas (APA) are relevant cause of endocrine related hypertension in Primary Aldosteronism (PA). Next generation sequencing techniques have identified somatic mutations in APA harbored in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1 and PRKACA genes. Yet, a number of APA harbor no mutations in candidate genes (designated as wild type, WT) and little is known about genotype/phenotype correlation. Objectives: We investigated the tissue-based molecular and histopathological characteristics of 132 APAs after laparoscopic unilateral adrenalectomy in PA-patients and studied genotype/morphometry and histopathology correlation. Methods: Tumor-DNA was screened for somatic mutations in candidate genes by targeted (n=84) or whole-exome (n=48) sequencing. Accurate characterization of 179 morphometric parameters and of immunohistochemistry (IHC) results for steroidogenic enzymes CYP11B1, CYP11B2, CYP17, HSD3B1 and HSD3B2 was performed on tumor tissue microarrays from all samples by digital image analysis. Results: Prevalence of WT APA in our cohort was 34% and affected men more frequently. In 8/48 APA, non-recurrent somatic mutations (NR) were identified. H&E analysis demonstrated that 6 morphometric parameters correlated negatively with WT status whereas those same parameters correlated positively with the presence of KCNJ5 or NR (PWT and KCNJ5 mutated APA was found in 10 cytoplasmic parameters, including mainly color-based features (PKCNJ5 mutation status was negatively correlated with CYP11B1 and HSD3B1 expression (PWT, CACNA1D and NR APA significantly correlated positively with CYP11B1. ATP1A1 mutated APA correlated positively with CYP11B2 (PNR APA point towards a KCNJ5-like morphometric pattern associated with a WT-like steroidogenic enzymes expression pattern. WT APA presented an opposed morphometric pattern in comparison to mutated APA, indicating that in absence of detectable somatic mutations APA cells are driven towards a different cellular fate.
- 21 February 2017
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 49 (03) , 208-213
Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy
Catecholamine excess from pheochromocytoma results in cardiovascular symptoms such as arterial hypertension and tachycardia and induces metabolic alterations including glucose intolerance and increase in resting metabolic rate. The objective of our study was to investigate the effect of surgical cure of pheochromocytoma on body-mass-index and the correlation of body-mass-index changes to preoperative endocrine parameters. Pheochromocytoma patients from the Munich ENSAT Registry were matched (1:2) for age and gender to patients from the German Conn’s Registry, who had undergone surgery for aldosterone-producing-adenomas. Thereby, 43 pheochromocytoma patients (17 males/26 females) and 86 aldosterone-producing-adenoma patients were analyzed for body-mass-index, blood pressure, and catecholamine levels before and one year after adrenalectomy. Seventy-four percent of pheochromocytoma patients were hypertensive preoperatively and 48% one year postoperatively. Systolic blood pressure did not differ significantly in pre- and postoperative measurements whereas diastolic blood pressure was significantly reduced over time. Moreover, pheochromocytoma patients gained body weight (p<0.001) one year following adrenalectomy accompanied by significant increases in body-mass-index, whereas aldosterone-producing adenoma patients displayed a slight weight loss. Despite weight gain, diagnosis of diabetes mellitus dropped from 9 of 43 investigated pheochromocytoma patients at baseline to 4 at follow-up. A significant correlation between body-mass-index changes to the preoperative catecholamine levels was found only for urinary normetanephrines. These data suggest that normalization of chronic catecholamine excess by adrenalectomy is associated with an increase in body-mass-index, which is more pronounced in patients with high preoperative levels of urinary normetanephrines.
- 21 February 2017
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 49 (03) , 208-213
Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy
Catecholamine excess from pheochromocytoma results in cardiovascular symptoms such as arterial hypertension and tachycardia and induces metabolic alterations including glucose intolerance and increase in resting metabolic rate. The objective of our study was to investigate the effect of surgical cure of pheochromocytoma on body-mass-index and the correlation of body-mass-index changes to preoperative endocrine parameters. Pheochromocytoma patients from the Munich ENSAT Registry were matched (1:2) for age and gender to patients from the German Conn’s Registry, who had undergone surgery for aldosterone-producing-adenomas. Thereby, 43 pheochromocytoma patients (17 males/26 females) and 86 aldosterone-producing-adenoma patients were analyzed for body-mass-index, blood pressure, and catecholamine levels before and one year after adrenalectomy. Seventy-four percent of pheochromocytoma patients were hypertensive preoperatively and 48% one year postoperatively. Systolic blood pressure did not differ significantly in pre- and postoperative measurements whereas diastolic blood pressure was significantly reduced over time. Moreover, pheochromocytoma patients gained body weight (p<0.001) one year following adrenalectomy accompanied by significant increases in body-mass-index, whereas aldosterone-producing adenoma patients displayed a slight weight loss. Despite weight gain, diagnosis of diabetes mellitus dropped from 9 of 43 investigated pheochromocytoma patients at baseline to 4 at follow-up. A significant correlation between body-mass-index changes to the preoperative catecholamine levels was found only for urinary normetanephrines. These data suggest that normalization of chronic catecholamine excess by adrenalectomy is associated with an increase in body-mass-index, which is more pronounced in patients with high preoperative levels of urinary normetanephrines.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Remission, recurrence and control rates in patients with ACTH-dependent Cushing's syndrome- a monocentric, retrospective analysis
Introduction: Transsphenoidal surgery is the gold standard in Cushing’s disease and recurrence is a major risk. We wondered which impact remission and recurrence might have on control rates of hypercortisolism and conducted a systematic analysis of our cohort of patients with Cushing’s syndrome after undergoing surgical therapy. Methods: We analysed the course of the disease in 74 patients with ACTH-dependent Cushing’s syndrome (63 Cushing’s disease (CD); 11 ectopic Cushing’s syndrome (ECS)). All patients underwent surgery as first line therapy and in cases where relapse occurred, each received further therapy. The outcomes of interest were biochemical remission/control, clinical remission and recurrence, with evaluations conducted annually from the time of first treatment (follow-up time: 1–38 years). Clinical remission was defined by the absence of Cushing stigmata. Biochemical remission/control was defined as normal urinary free cortisol levels, normal salivary cortisol levels at midnight and/or cortisol <1.8 μg/dl after 1 mg overnight dexamethasone suppression test. Data analysis was conducted using the Kaplan-Meier method. Results: In patients with CD the biochemical control rates at 1, 2 and 3 years were 77.2, 81.8, and 77.2%. In contrast, patients with ECS showed considerably higher remission rates with 88.8% at 1 year and 100% at 2 and 3 years. The cumulative recurrence free remission rate in CD was 71.4% at 1 and 2, and 54.2% at 5 years. In patients having second transsphenoidal surgery the remission rate was poor with 50% at 1 and 2 years, and 40% at 5 years. Conclusions: The outcome of patients in remission 1 year after initial surgery is associated with higher remission rates in the long term, while the absence of remission after 1 year, or the occurrence of early relapse are related to a noticeably poorer outcome.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Remission, recurrence and control rates in patients with ACTH-dependent Cushing's syndrome- a monocentric, retrospective analysis
Introduction: Transsphenoidal surgery is the gold standard in Cushing’s disease and recurrence is a major risk. We wondered which impact remission and recurrence might have on control rates of hypercortisolism and conducted a systematic analysis of our cohort of patients with Cushing’s syndrome after undergoing surgical therapy. Methods: We analysed the course of the disease in 74 patients with ACTH-dependent Cushing’s syndrome (63 Cushing’s disease (CD); 11 ectopic Cushing’s syndrome (ECS)). All patients underwent surgery as first line therapy and in cases where relapse occurred, each received further therapy. The outcomes of interest were biochemical remission/control, clinical remission and recurrence, with evaluations conducted annually from the time of first treatment (follow-up time: 1–38 years). Clinical remission was defined by the absence of Cushing stigmata. Biochemical remission/control was defined as normal urinary free cortisol levels, normal salivary cortisol levels at midnight and/or cortisol <1.8 μg/dl after 1 mg overnight dexamethasone suppression test. Data analysis was conducted using the Kaplan-Meier method. Results: In patients with CD the biochemical control rates at 1, 2 and 3 years were 77.2, 81.8, and 77.2%. In contrast, patients with ECS showed considerably higher remission rates with 88.8% at 1 year and 100% at 2 and 3 years. The cumulative recurrence free remission rate in CD was 71.4% at 1 and 2, and 54.2% at 5 years. In patients having second transsphenoidal surgery the remission rate was poor with 50% at 1 and 2 years, and 40% at 5 years. Conclusions: The outcome of patients in remission 1 year after initial surgery is associated with higher remission rates in the long term, while the absence of remission after 1 year, or the occurrence of early relapse are related to a noticeably poorer outcome.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
PRKACA somatic mutations are rare in aldosterone-producing adenomas.
Aldosterone-producing adenomas (APAs) are the most frequent cause of primary aldosteronism (PA). Somatic mutations of KCNJ5, ATP1A1, CACNA1D and ATP2B3 are involved in APAs formation while CTNNB1 and GNAS somatic mutations have been described in both APAs and in cortisol-producing adenomas (CPAs). In contrast, mutations of PRKACA coding for the catalytic subunit of protein kinase A have been yet only identified in CPAs. We investigated a consecutive series of APAs from 122 Conn-patients after unilateral adrenalectomy. We performed exome or bidirectional Sanger sequencing of tumor-tissue and evaluated mutations in candidate genes as well as PRKACA. Exome sequencing revealed PRKACA somatic mutations in two APAs (1.6%). One APA carried a L206R mutation, previously described only in cortisol-producing adenoma with overt Cushing’s syndrome, while in the second case a newly identified H88D mutation was found. Both affected patients were females with hypokalemic hypertension, aldosterone excess and lateralization during adrenal venous sampling. We functionally characterized the enzymatic activity of L206R and H88D mutated PKA catalytic subunit in vitro and characterized the immunoexpression of steroidogenic enzymes in affected tissues. Functional analysis showed that the newly found H88D mutation was not associated with gain of function of PKA. Interestingly, while CYP11B2 expression was found in the H88D-mutated APA, no co-expression of CYP11B1 was present. In contrast, in the L206R-mutated APA, CYP11B1 was expressed while CYP11B2 was weak or negative. Accordingly, biochemical Cushing’s syndrome was present only in the patient with the L206R mutation. Following adrenalectomy, both patients improved with a reduced number of antihypertensive medications and normalized potassium levels. We describe here for the first time PRKACA mutations in APAs as rare findings associated with PA. As cortisol co-secretion occurs in a sub-group of APAs other molecular mechanisms are likely to exist.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
PRKACA somatic mutations are rare in aldosterone-producing adenomas.
Aldosterone-producing adenomas (APAs) are the most frequent cause of primary aldosteronism (PA). Somatic mutations of KCNJ5, ATP1A1, CACNA1D and ATP2B3 are involved in APAs formation while CTNNB1 and GNAS somatic mutations have been described in both APAs and in cortisol-producing adenomas (CPAs). In contrast, mutations of PRKACA coding for the catalytic subunit of protein kinase A have been yet only identified in CPAs. We investigated a consecutive series of APAs from 122 Conn-patients after unilateral adrenalectomy. We performed exome or bidirectional Sanger sequencing of tumor-tissue and evaluated mutations in candidate genes as well as PRKACA. Exome sequencing revealed PRKACA somatic mutations in two APAs (1.6%). One APA carried a L206R mutation, previously described only in cortisol-producing adenoma with overt Cushing’s syndrome, while in the second case a newly identified H88D mutation was found. Both affected patients were females with hypokalemic hypertension, aldosterone excess and lateralization during adrenal venous sampling. We functionally characterized the enzymatic activity of L206R and H88D mutated PKA catalytic subunit in vitro and characterized the immunoexpression of steroidogenic enzymes in affected tissues. Functional analysis showed that the newly found H88D mutation was not associated with gain of function of PKA. Interestingly, while CYP11B2 expression was found in the H88D-mutated APA, no co-expression of CYP11B1 was present. In contrast, in the L206R-mutated APA, CYP11B1 was expressed while CYP11B2 was weak or negative. Accordingly, biochemical Cushing’s syndrome was present only in the patient with the L206R mutation. Following adrenalectomy, both patients improved with a reduced number of antihypertensive medications and normalized potassium levels. We describe here for the first time PRKACA mutations in APAs as rare findings associated with PA. As cortisol co-secretion occurs in a sub-group of APAs other molecular mechanisms are likely to exist.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Paradoxical worsening of lipid metabolism after successful treatment of primary aldosteronism
Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Aldosterone itself represents a BP-independent cardiovascular risk factor associated with increased rates of morbidity and mortality. Recently a worsening of lipid metabolism after treatment has been described. Objective: Our aim was to analyse changes in lipid parameters according to treatment outcome in PA patients. Data of 215 consecutive PA patients with unilateral aldosterone-producing adenoma (APA, n=144) or bilateral idiopathic adrenal hyperplasia (IHA, n=71) were extracted from the database of the German Conn’s Registry. To assess the metabolic outcome, they were investigated before, one year and three years after treatment by adrenalectomy (ADX) or by MR-antagonist (MRA). Results: One year after initiation of treatment potassium had been normalized in all patients. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) changed inversely. HDL-C was significantly lower in patients with APA (53.00 (45.3; 67) vs 52.00 (44; 65) mg/dl, P=0.046) and IHA (52.00 (42; 66) vs 48.00 (39; 62) mg/dl, P=0.004) after treatment. TG were significantly higher in both subgroups at follow-up (APA 103.5 (69.3; 148.0) vs 111.0 (78.3; 166.5) mg/dl, P=0.000; IHA 111.0 (82; 150) vs 129.0 (85; 195) mg/dl, P=0.020), whereas BMI remained unchanged and fasting plasma glucose (FPG) even improved in follow-up patients with APA (99.0 (90; 109) vs 95.0 (88; 104) mg/dl, P=0.004). Changes in the HDL-C-to-TG ratio at one year follow-up correlated with decrease of GFR (β=0.184, P=0.024) in multivariate analysis but not with change in potassium, urea or urine albumin-to-creatinine ratio (ACR). After two more years there was a slight further decline in GFR (P=0.012), whereas HDL-C remained stable. Conclusion: Our results show that treatment of PA is associated with a worsening of lipid parameters despite improved glucose parameters and stable BMI. This paradoxical effect could be explained by renal dysfunction following ADX or MRA treatment caused by a decrease in glomerular hyperfiltration. In view of stable low-density lipoprotein cholesterol, reduced albuminuria, FPG and blood pressure, however, a higher risk for atherosclerosis in patients with PA after treatment seems unlikely.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Paradoxical worsening of lipid metabolism after successful treatment of primary aldosteronism
Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Aldosterone itself represents a BP-independent cardiovascular risk factor associated with increased rates of morbidity and mortality. Recently a worsening of lipid metabolism after treatment has been described. Objective: Our aim was to analyse changes in lipid parameters according to treatment outcome in PA patients. Data of 215 consecutive PA patients with unilateral aldosterone-producing adenoma (APA, n=144) or bilateral idiopathic adrenal hyperplasia (IHA, n=71) were extracted from the database of the German Conn’s Registry. To assess the metabolic outcome, they were investigated before, one year and three years after treatment by adrenalectomy (ADX) or by MR-antagonist (MRA). Results: One year after initiation of treatment potassium had been normalized in all patients. High-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) changed inversely. HDL-C was significantly lower in patients with APA (53.00 (45.3; 67) vs 52.00 (44; 65) mg/dl, P=0.046) and IHA (52.00 (42; 66) vs 48.00 (39; 62) mg/dl, P=0.004) after treatment. TG were significantly higher in both subgroups at follow-up (APA 103.5 (69.3; 148.0) vs 111.0 (78.3; 166.5) mg/dl, P=0.000; IHA 111.0 (82; 150) vs 129.0 (85; 195) mg/dl, P=0.020), whereas BMI remained unchanged and fasting plasma glucose (FPG) even improved in follow-up patients with APA (99.0 (90; 109) vs 95.0 (88; 104) mg/dl, P=0.004). Changes in the HDL-C-to-TG ratio at one year follow-up correlated with decrease of GFR (β=0.184, P=0.024) in multivariate analysis but not with change in potassium, urea or urine albumin-to-creatinine ratio (ACR). After two more years there was a slight further decline in GFR (P=0.012), whereas HDL-C remained stable. Conclusion: Our results show that treatment of PA is associated with a worsening of lipid parameters despite improved glucose parameters and stable BMI. This paradoxical effect could be explained by renal dysfunction following ADX or MRA treatment caused by a decrease in glomerular hyperfiltration. In view of stable low-density lipoprotein cholesterol, reduced albuminuria, FPG and blood pressure, however, a higher risk for atherosclerosis in patients with PA after treatment seems unlikely.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation
Genetic alterations affecting the PKA/cAMP pathway are commonly found in cortisol-producing adrenocortical adenomas (ACAs), while activating mutations in the gene coding for β-catenin (CTNNB1) have been reported in both adenomas and carcinomas. However, the molecular pathogenesis of most ACAs is still unclear. Aim of the study was a comprehensive genetic characterization of sporadic ACAs and the identification of novel molecular markers involved in adrenal tumorigenesis and steroid autonomy. Whole-exome sequencing was performed on DNA of adrenocortical tumors and corresponding blood samples of 99 patients with ACAs (39 associated with overt Cushing’s syndrome, 35 with subclinical hypercortisolism and 25 endocrine inactive) negative for the p.Leu206Arg PRKACA mutation. In total, 706 protein-altering somatic mutations were detected in 88/99 ACAs (median: 6 mutations per sample, range: 0–55). Several altered genes could be recognized as part of the Wnt/β-catenin pathway (CTNNB1, APC, APC2, PKP2, and different members of the protocadherin superfamily), being associated with larger tumor size and endocrine inactivity. Moreover, many components of the cAMP/PKA pathway were affected by somatic mutations, including three new mutations in the PRKACA gene, mutations in metabotropic glutamate receptors (GRM3, GRM4, GRM6) and others (GNAS, PRKACA, PRKAR1A, CREB1, CREBBP, ADCY3), and associated with female gender and overt Cushing syndrome. Finally, more surprisingly, we also observed several alterations in genes involved in the Ca2+ signaling (CACNA1C, CACNA1E, RYR1, RYR2, RYR3, GRIA1, GRID1, GRIK2, GRIN1, GRIN3B, GRIP1, GRIA2). In conclusion, this study represents the most comprehensive genetic characterization of unilateral ACAs, including inactive adenomas. We thereby identified somatic alterations affecting signaling pathways known or potentially involved in the adrenal tumorigenesis.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation
Genetic alterations affecting the PKA/cAMP pathway are commonly found in cortisol-producing adrenocortical adenomas (ACAs), while activating mutations in the gene coding for β-catenin (CTNNB1) have been reported in both adenomas and carcinomas. However, the molecular pathogenesis of most ACAs is still unclear. Aim of the study was a comprehensive genetic characterization of sporadic ACAs and the identification of novel molecular markers involved in adrenal tumorigenesis and steroid autonomy. Whole-exome sequencing was performed on DNA of adrenocortical tumors and corresponding blood samples of 99 patients with ACAs (39 associated with overt Cushing’s syndrome, 35 with subclinical hypercortisolism and 25 endocrine inactive) negative for the p.Leu206Arg PRKACA mutation. In total, 706 protein-altering somatic mutations were detected in 88/99 ACAs (median: 6 mutations per sample, range: 0–55). Several altered genes could be recognized as part of the Wnt/β-catenin pathway (CTNNB1, APC, APC2, PKP2, and different members of the protocadherin superfamily), being associated with larger tumor size and endocrine inactivity. Moreover, many components of the cAMP/PKA pathway were affected by somatic mutations, including three new mutations in the PRKACA gene, mutations in metabotropic glutamate receptors (GRM3, GRM4, GRM6) and others (GNAS, PRKACA, PRKAR1A, CREB1, CREBBP, ADCY3), and associated with female gender and overt Cushing syndrome. Finally, more surprisingly, we also observed several alterations in genes involved in the Ca2+ signaling (CACNA1C, CACNA1E, RYR1, RYR2, RYR3, GRIA1, GRID1, GRIK2, GRIN1, GRIN3B, GRIP1, GRIA2). In conclusion, this study represents the most comprehensive genetic characterization of unilateral ACAs, including inactive adenomas. We thereby identified somatic alterations affecting signaling pathways known or potentially involved in the adrenal tumorigenesis.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Is steroid profiling using LC-MS/MS useful in the diagnostic work-up of primary aldosteronism?
Introduction: Primary aldosteronism (PA) is mainly caused by unilateral aldosterone-producing adenomas (APA) or bilateral adrenal hyperplasia (BAH). Subtype differentiation relies on the invasive and technically challenging adrenal venous sampling (AVS). We recently demonstrated the potential utility of peripheral plasma steroid profiling by LC-MS/MS to distinguish APA and BAH. We tested the following hypotheses: first, if steroid profiling in combination with AVS, effectively identifies patients with unilateral disease who are candidates for surgery and second, if steroid profiling identifies those patients with a high likelihood for BAH in whom AVS may be avoided. Methods: Two hundred and eight confirmed PA patients underwent computed tomography, AVS and steroid profiling of peripheral plasma by LC-MS/MS. Long-term outcome of adrenalectomy was assessed by clinical and biochemical re-evaluation in all subjects. The diagnostic accuracy for subtyping PA patients was calculated based on different strategies for PA subtype differentiation and compared to the gold standard of AVS. Results: The diagnostic accuracy of AVS was 97%, with 6 out of 121 APA patients incorrectly classified on the basis of persistent PA following adrenalectomy. Steroid profiling correctly classified 79% of PA patients but this does not identify the adrenal source of aldosterone excess for the APA group. The most effective strategy in our model was steroid profiling followed by selective AVS in those patients designated by peripheral venous steroid profiling to have high likelihood of an APA. Here, 20 patients would have been falsely classified and treated as BAH while 6 patients with BAH falsely classified as APA by AVS would have been spared unnecessary adrenalectomy. Notably, the requirements for AVS would have been reduced by 43%. Conclusion: Steroid profiling followed by AVS in the APA group could provide an alternative to AVS alone for subtype differentiation in PA patients, thereby significantly reducing the need for AVS.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Is steroid profiling using LC-MS/MS useful in the diagnostic work-up of primary aldosteronism?
Introduction: Primary aldosteronism (PA) is mainly caused by unilateral aldosterone-producing adenomas (APA) or bilateral adrenal hyperplasia (BAH). Subtype differentiation relies on the invasive and technically challenging adrenal venous sampling (AVS). We recently demonstrated the potential utility of peripheral plasma steroid profiling by LC-MS/MS to distinguish APA and BAH. We tested the following hypotheses: first, if steroid profiling in combination with AVS, effectively identifies patients with unilateral disease who are candidates for surgery and second, if steroid profiling identifies those patients with a high likelihood for BAH in whom AVS may be avoided. Methods: Two hundred and eight confirmed PA patients underwent computed tomography, AVS and steroid profiling of peripheral plasma by LC-MS/MS. Long-term outcome of adrenalectomy was assessed by clinical and biochemical re-evaluation in all subjects. The diagnostic accuracy for subtyping PA patients was calculated based on different strategies for PA subtype differentiation and compared to the gold standard of AVS. Results: The diagnostic accuracy of AVS was 97%, with 6 out of 121 APA patients incorrectly classified on the basis of persistent PA following adrenalectomy. Steroid profiling correctly classified 79% of PA patients but this does not identify the adrenal source of aldosterone excess for the APA group. The most effective strategy in our model was steroid profiling followed by selective AVS in those patients designated by peripheral venous steroid profiling to have high likelihood of an APA. Here, 20 patients would have been falsely classified and treated as BAH while 6 patients with BAH falsely classified as APA by AVS would have been spared unnecessary adrenalectomy. Notably, the requirements for AVS would have been reduced by 43%. Conclusion: Steroid profiling followed by AVS in the APA group could provide an alternative to AVS alone for subtype differentiation in PA patients, thereby significantly reducing the need for AVS.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Plasma metabolomics profile in patients with Cushing's syndrome
Background: Cushing’s syndrome (CS) is a chronic disorder characterized by endogenous cortisol excess resulting in long-term metabolic and cardiovascular consequences. The identification of metabolic alterations related to hypercortisolism could be beneficial in tailoring treatments of co-morbidities. Our aim was to characterize the metabolic alterations of patients with hypercortisolism by targeted plasma metabolomic profiling. Methods: Subjects (n=149) were recruited from three German centers (Munich, Berlin, and Würzburg) belonging to the German Cushing registry (CUSTODES) and the European Network for the Study of Adrenal Tumors (ENSAT). According to clinical and hormonal characteristics, four groups were identified: non-secreting adrenocortical adenomas (NS) (n=27), subclinical hypercortisolism (SH) (n=34), CS (n=46), and patients in whom CS has been excluded (EC) (n=42). Plasma targeted metabolomics profiling was performed using the mass spectrometry-based kit AbsoluteIDQ-p180 (BIOCRATES AG, Austria). Results: Metabolic profile of patients with CS was characterized by reduced carnitine and acetyl-carnitine levels, with respect to EC. Polyamine levels were increased in CS patients, whereas several glucogenic amino acids were decreased, when compared to EC. Similar alterations were also identified in SH patients. Spermidine was progressively increased among NS, SH, and CS patients, and showed positive correlation with post-DST cortisol (Coefficient=0.341, P<0.001). Serotonin levels were increased in adrenal-dependent hypercortisolism (SH and CS), when compared to EC, NS, and ACTH-dependent CS. Logistic regression analysis showed that the panel of significant metabolites among groups was able to correctly classify 83.8% of the patients. Three scores were identified from logistic regression that showed good accuracy in discriminating CS vs. EC, CS vs SH, and SH vs NS (sensitivity/specificity of 87%/83%, 89%/88%, and 78%/74%, respectively). Conclusion: Metabolomic profiling revealed the presence of several disturbances in patients with hypercortisolism, mainly involving polyamine and amino acids metabolism, and β-oxidation. Metabolomic analysis showed also good accuracy in classifying patients with hypercortisolism according to their specific metabolic profile. Further studies are currently ongoing to analyze a large cohort of matched normal control subjects.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Plasma metabolomics profile in patients with Cushing's syndrome
Background: Cushing’s syndrome (CS) is a chronic disorder characterized by endogenous cortisol excess resulting in long-term metabolic and cardiovascular consequences. The identification of metabolic alterations related to hypercortisolism could be beneficial in tailoring treatments of co-morbidities. Our aim was to characterize the metabolic alterations of patients with hypercortisolism by targeted plasma metabolomic profiling. Methods: Subjects (n=149) were recruited from three German centers (Munich, Berlin, and Würzburg) belonging to the German Cushing registry (CUSTODES) and the European Network for the Study of Adrenal Tumors (ENSAT). According to clinical and hormonal characteristics, four groups were identified: non-secreting adrenocortical adenomas (NS) (n=27), subclinical hypercortisolism (SH) (n=34), CS (n=46), and patients in whom CS has been excluded (EC) (n=42). Plasma targeted metabolomics profiling was performed using the mass spectrometry-based kit AbsoluteIDQ-p180 (BIOCRATES AG, Austria). Results: Metabolic profile of patients with CS was characterized by reduced carnitine and acetyl-carnitine levels, with respect to EC. Polyamine levels were increased in CS patients, whereas several glucogenic amino acids were decreased, when compared to EC. Similar alterations were also identified in SH patients. Spermidine was progressively increased among NS, SH, and CS patients, and showed positive correlation with post-DST cortisol (Coefficient=0.341, P<0.001). Serotonin levels were increased in adrenal-dependent hypercortisolism (SH and CS), when compared to EC, NS, and ACTH-dependent CS. Logistic regression analysis showed that the panel of significant metabolites among groups was able to correctly classify 83.8% of the patients. Three scores were identified from logistic regression that showed good accuracy in discriminating CS vs. EC, CS vs SH, and SH vs NS (sensitivity/specificity of 87%/83%, 89%/88%, and 78%/74%, respectively). Conclusion: Metabolomic profiling revealed the presence of several disturbances in patients with hypercortisolism, mainly involving polyamine and amino acids metabolism, and β-oxidation. Metabolomic analysis showed also good accuracy in classifying patients with hypercortisolism according to their specific metabolic profile. Further studies are currently ongoing to analyze a large cohort of matched normal control subjects.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Expression and mutational status of USP8 in tumours causing ectopic Cushing's syndrome
Introduction: Mutations activating USP8 have been detected in a high proportion of pituitary adenomas causing Cushing’s disease and have been linked to an increase of ACTH production in corticotroph cells. Whether USP8 mutations are involved in the tumorigenesis of the ectopic Cushing’s syndrome (ECS) caused by neuroendocrine tumors has not been studied. Patients and methods: In this work we evaluate the role of USP8 in a series of 17 tumors from patients diagnosed with ECS by analyzing the expression of ACTH, EGFR and USP8 by immunohistochemistry, as well as the rate of mutations of USP8 using Sanger sequencing. USP8 expression was related to different clinical parameters and its action was studied in vitro. Results: USP8 was found to be widely expressed in all examined tumors, although at different levels. Sanger sequencing did not detect heterozygous mutations in the USP8 gene. ACTH immunoreactivity was detected in 11/17 tumors (65%). The majority of ECS (12/17; 71%) had no or weak EGFR expression. No significant association was observed between USP8 immunoreactivity and clinical data, such as age, sex, BMI, hormonal levels or overall survival. Overexpressing USP8 and EGFR in the bronchial carcinoid cell line NCI-H727 – that does not synthesize ACTH – failed to trigger exogenous Pomc promoter activity. Conclusions: Altogether these results suggest that, despite their role in pituitary tumors, neither USP8 nor EGFR are actively contributing to the ectopic production of ACTH.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
Expression and mutational status of USP8 in tumours causing ectopic Cushing's syndrome
Introduction: Mutations activating USP8 have been detected in a high proportion of pituitary adenomas causing Cushing’s disease and have been linked to an increase of ACTH production in corticotroph cells. Whether USP8 mutations are involved in the tumorigenesis of the ectopic Cushing’s syndrome (ECS) caused by neuroendocrine tumors has not been studied. Patients and methods: In this work we evaluate the role of USP8 in a series of 17 tumors from patients diagnosed with ECS by analyzing the expression of ACTH, EGFR and USP8 by immunohistochemistry, as well as the rate of mutations of USP8 using Sanger sequencing. USP8 expression was related to different clinical parameters and its action was studied in vitro. Results: USP8 was found to be widely expressed in all examined tumors, although at different levels. Sanger sequencing did not detect heterozygous mutations in the USP8 gene. ACTH immunoreactivity was detected in 11/17 tumors (65%). The majority of ECS (12/17; 71%) had no or weak EGFR expression. No significant association was observed between USP8 immunoreactivity and clinical data, such as age, sex, BMI, hormonal levels or overall survival. Overexpressing USP8 and EGFR in the bronchial carcinoid cell line NCI-H727 – that does not synthesize ACTH – failed to trigger exogenous Pomc promoter activity. Conclusions: Altogether these results suggest that, despite their role in pituitary tumors, neither USP8 nor EGFR are actively contributing to the ectopic production of ACTH.
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Urine steroid metabolomics as a diagnostic tool in primary aldosteronism
Introduction: The regular diagnostic workup for primary aldosteronism (PA) can be very demanding and involves multiple invasive as well as time and cost intensive diagnostic tests. Here we have explored the value of urinary steroid metabolome analysis in the diagnosis and differential diagnosis of PA. Previously, urinary 3α,5β-tetrahydroaldosterone (THAldo) has been suggested as a reliable screening test for PA and serum 18-oxocortisol and 18-hydroxycortisol have been reported as diagnostic markers with the potential to distinguish unilateral aldosterone-producing adenomas (APA) from bilateral adrenal hyperplasia (BAH). Patients and methods: We studied 180 PA patients (103 APA, 71 BAH) in whom PA had been confirmed by saline infusion test followed by adrenal vein sampling for subtype differentiation. We carried out targeted sequencing for disease-causing somatic mutations in the KCNJ5, CACNA1D, ATP1A1 and ATP2B3 genes in tumour tissue obtained by unilateral adrenalectomy, which was available in 75/103 APA patients. The urine steroid metabolome was analysed by gas chromatography-mass spectrometry comprising the quantification of 38 distinct steroids including metabolites of aldosterone, deoxycorticosterone, corticosterone as well as 18OH-cortisol (18OH-F) and 18-oxo-tetrahydrocortisol (18oxo-THF). Results: As expected, urinary excretion of mineralocorticoids (p69 μg/24h, with significantly higher THAldo in APAs compared to BAH (p=0.0082). Similarly, APAs had significantly higher excretion of 18OH-F (p=0.0171) and 18oxo-THF (p=0.0005). Genetic analysis of APA tissue revealed mutations in KCNJ5 (n=29), ATPases (n=12) and CACNA1D (n=6) while in 28 patients no known mutation was identified. Patients with KCNJ5 mutations had significantly increased excretion of both 18OH-F (p=0.0002) and 18oxo-THF (p<0.0001) as compared to the other mutation groups. Conclusion: Urine steroid metabolomics is a promising approach for the diagnosis and differential diagnosis of PA
- 12 October 2015
- Published by Bioscientifica in Endocrine Abstracts
Urine steroid metabolomics as a diagnostic tool in primary aldosteronism
Introduction: The regular diagnostic workup for primary aldosteronism (PA) can be very demanding and involves multiple invasive as well as time and cost intensive diagnostic tests. Here we have explored the value of urinary steroid metabolome analysis in the diagnosis and differential diagnosis of PA. Previously, urinary 3α,5β-tetrahydroaldosterone (THAldo) has been suggested as a reliable screening test for PA and serum 18-oxocortisol and 18-hydroxycortisol have been reported as diagnostic markers with the potential to distinguish unilateral aldosterone-producing adenomas (APA) from bilateral adrenal hyperplasia (BAH). Patients and methods: We studied 180 PA patients (103 APA, 71 BAH) in whom PA had been confirmed by saline infusion test followed by adrenal vein sampling for subtype differentiation. We carried out targeted sequencing for disease-causing somatic mutations in the KCNJ5, CACNA1D, ATP1A1 and ATP2B3 genes in tumour tissue obtained by unilateral adrenalectomy, which was available in 75/103 APA patients. The urine steroid metabolome was analysed by gas chromatography-mass spectrometry comprising the quantification of 38 distinct steroids including metabolites of aldosterone, deoxycorticosterone, corticosterone as well as 18OH-cortisol (18OH-F) and 18-oxo-tetrahydrocortisol (18oxo-THF). Results: As expected, urinary excretion of mineralocorticoids (p69 μg/24h, with significantly higher THAldo in APAs compared to BAH (p=0.0082). Similarly, APAs had significantly higher excretion of 18OH-F (p=0.0171) and 18oxo-THF (p=0.0005). Genetic analysis of APA tissue revealed mutations in KCNJ5 (n=29), ATPases (n=12) and CACNA1D (n=6) while in 28 patients no known mutation was identified. Patients with KCNJ5 mutations had significantly increased excretion of both 18OH-F (p=0.0002) and 18oxo-THF (p<0.0001) as compared to the other mutation groups. Conclusion: Urine steroid metabolomics is a promising approach for the diagnosis and differential diagnosis of PA